Trout Group is providing IR counsel to Bellicum Pharmaceuticals as the Houston-based biotech company eyes an initial public offering worth up to $115M.
New York counselor Brad Miles of BMC Communications advises Bellicum on the PR front. Trout Group VP Peter Rahmer, a biotech specialist, reps the company for the New York-based IR firm.
Bellicum, which develops immunotherapies that fight cancers, filed Nov. 18.. The clinical stage company recently landed $55M in a Series C round of funding.
Bellicum reported an $8M loss from operations in 2013 and an accumulated deficit of $38.6M.
Xconomy.com noted the company would be the first Houston biotech to go public in 15 years.
Edelman handles Viking Holdings, the river and ocean luxury cruise line that plans to raise $1B via an IPO priced in the $21 to $25 per share range.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Tod Donhauser, a nine-year veteran of Edelman, has joined H/Advisors Abernathy as managing director and head of its San Francisco office.
Intelligent Group Ltd, a Hong Kong-based financial PR firm, has priced its initial public offering of 1.9M shares at $4, which is the low end of the $4 to $5 range.
Have a comment? Send it to 
No comments have been submitted for this story yet.